Login to Your Account

Fibroid optics: Street eyes next phase III as Allergan, Gedeon chalk up first win

By Randy Osborne
Staff Writer

Monday, May 9, 2016

With positive phase III data in hand and another study under way, Allergan plc with partner Gedeon Richter plc could be on their way to the first non-invasive, long-term option for women with uterine fibroids in the U.S., as the therapeutic space gains momentum.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription